EWA
FHTX icon

EverSource Wealth Advisors’s Foghorn Therapeutics FHTX Stock Holding History

EverSource Wealth Advisors’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$883 Buy
181
+99
+121% +$439 ﹤0.01% 4004
2026
Q1 		$392 Buy
82
+7
+9% +$38 ﹤0.01% 4103
2025
Q4 		$405 Hold
75
– – ﹤0.01% 3916
2025
Q3 		$367 Hold
75
– – ﹤0.01% 4018
2025
Q2 		$353 Sell
75
-21
-22% -$88 ﹤0.01% 3976
2025
Q1 		$350 Buy
+96
New +$438 ﹤0.01% 3570

Other funds holding FHTX

Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
DT
Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
SO
STRS Ohio Columbus, Ohio $26.7B AUM 43.32% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

EverSource Wealth Advisors's FHTX Position: Q2 2026 in Review

EverSource Wealth Advisors increased its Foghorn Therapeutics (FHTX) stake by 121% in Q2 2026, buying an estimated $439 and bringing the position to 181 shares worth $883. The position accounts for ﹤0.01% of the portfolio, ranked #4004.

EverSource Wealth Advisors first reported a position in FHTX in Q1 2025 and has held it in 6 quarters since. 18 funds tracked by Wall St. Rank hold FHTX as of Q2 2026.

  • EverSource Wealth Advisors held 181 shares of Foghorn Therapeutics worth $883 as of Q2 2026.
  • EverSource Wealth Advisors bought 99 Foghorn Therapeutics shares in Q2 2026, an estimated $439.
  • Foghorn Therapeutics made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #4004 holding.
  • EverSource Wealth Advisors first reported a position in Foghorn Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 18 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.